(Q28219758)

https://api.crossref.org/works/10.1038%2FNCPRHEUM0432

Treatment of antiphospholipid antibody syndrome (APS) in pregnancy: a randomized pilot trial comparing low molecular weight heparin to unfractionated heparin

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0432

Activation of the Complement Pathway: Comparison of Normal Pregnancy, Preeclampsia, and Systemic Lupus Erythematosus During Pregnancy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0432

International consensus statement on preliminary classification criteria for definite antiphospholipid syndrome: report of an international workshop

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0432

7 January 2021

International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS)

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0432

7 January 2021

Anti-phospholipid antibodies are directed against a complex antigen that includes a lipid-binding inhibitor of coagulation: beta 2-glycoprotein I (apolipoprotein H)

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0432

7 January 2021

Anticardiolipin antibodies (ACA) directed not to cardiolipin but to a plasma protein cofactor

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0432

7 January 2021

Anticardiolipin cofactor(s) and differential diagnosis of autoimmune disease

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0432

7 January 2021

Endothelial cells as target for antiphospholipid antibodies. Human Polyclonal and Monoclonal Anti-β2-Glycoprotein I Antibodies React In Vitro with Endothelial Cells Through Adherent β2-Glycoprotein I and Induce Endothelial Activation

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0432

7 January 2021

Activation of cultured vascular endothelial cells by antiphospholipid antibodies.

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0432

7 January 2021

Characterization of monocyte tissue factor activity induced by IgG antiphospholipid antibodies and inhibition by dilazep

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0432

7 January 2021

Role of the MyD88 transduction signaling pathway in endothelial activation by antiphospholipid antibodies

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0432

7 January 2021

High affinity binding of beta 2-glycoprotein I to human endothelial cells is mediated by annexin II

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0432

7 January 2021

Dimers of beta 2-glycoprotein I increase platelet deposition to collagen via interaction with phospholipids and the apolipoprotein E receptor 2'

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0432

7 January 2021

Antibody-mediated interference with annexins in the antiphospholipid syndrome

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0432

7 January 2021

Research around beta 2-glycoprotein I: a major target for antiphospholipid antibodies

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0432

7 January 2021

Antiphospholipid antibodies affect trophoblast gonadotropin secretion and invasiveness by binding directly and through adhered beta2-glycoprotein I.

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0432

7 January 2021

Management of the obstetric antiphospholipid syndrome

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0432

7 January 2021

Complement C3 activation is required for antiphospholipid antibody-induced fetal loss

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0432

7 January 2021

Complement C5a receptors and neutrophils mediate fetal injury in the antiphospholipid syndrome

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0432

7 January 2021

Requirement of activation of complement C3 and C5 for antiphospholipid antibody-mediated thrombophilia

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0432

7 January 2021

A critical role for murine complement regulator crry in fetomaternal tolerance

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0432

7 January 2021

Negligible role of antibodies and C5 in pregnancy loss associated exclusively with C3-dependent mechanisms through complement alternative pathway

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0432

7 January 2021

The placental bed in pregnancies complicated by primary antiphospholipid syndrome

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0432

7 January 2021

Recurrent miscarriage and long-term thrombosis risk: a case-control study.

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0432

7 January 2021

The HELLP syndrome in the antiphospholipid syndrome: retrospective study of 16 cases in 15 women

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0432

7 January 2021

Assessing disease activity in SLE patients during pregnancy

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0432

7 January 2021

Placental pathology in systemic lupus erythematosus: a prospective study

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0432

7 January 2021

Placental pathology and antiphospholipid antibodies: a descriptive study

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0432

7 January 2021

Effects of Mothers' Autoimmune Disease During Pregnancy on Learning Disabilities and Hand Preference in Their Children

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0432

7 January 2021

Neuropsychological development of children born to patients with systemic lupus erythematosus.

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0432

7 January 2021

Prevention of recurrent miscarriage for women with antiphospholipid antibody or lupus anticoagulant

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0432

7 January 2021

Treatment of antiphospholipid syndrome in pregnancy--a systematic review of randomized therapeutic trials

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0432

7 January 2021

Repeated fetal losses associated with antiphospholipid antibodies: a collaborative randomized trial comparing prednisone with low-dose heparin treatment

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0432

7 January 2021

Comparative trial of prednisone plus aspirin versus aspirin alone in the treatment of anticardiolipin antibody-positive obstetric patients

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0432

7 January 2021

Antiphospholipid antibody-associated recurrent pregnancy loss: treatment with heparin and low-dose aspirin is superior to low-dose aspirin alone

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0432

7 January 2021

Pharmacokinetics of low molecular weight heparin and unfractionated heparin in pregnancy.

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0432

7 January 2021

Antiphospholipid antibodies associated with recurrent pregnancy loss: prospective, multicenter, controlled pilot study comparing treatment with low-molecular-weight heparin versus unfractionated heparin

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0432

7 January 2021

Treatment of pregnant patients with antiphospholipid syndrome

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0432

7 January 2021

What we have learned about preeclampsia

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0432

7 January 2021

Heparin and aspirin attenuate placental apoptosis in vitro: implications for early pregnancy failure

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0432

7 January 2021

Prednisone does not prevent recurrent fetal death in women with antiphospholipid antibody

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0432

7 January 2021

Intravenous immunoglobulin in pregnancies complicated by the antiphospholipid syndrome: what is its role?

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0432

7 January 2021

IVIG in APS pregnancy

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0432

7 January 2021

A multicenter, placebo-controlled pilot study of intravenous immune globulin treatment of antiphospholipid syndrome during pregnancy. The Pregnancy Loss Study Group

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0432

7 January 2021

Thrombocytopenia in pregnancy: differential diagnosis, pathogenesis, and management

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0432

7 January 2021

Differential interactions of heparin and heparan sulfate glycosaminoglycans with the selectins. Implications for the use of unfractionated and low molecular weight heparins as therapeutic agents

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0432

7 January 2021

Heparin's anti-inflammatory effects require glucosamine 6-O-sulfation and are mediated by blockade of L- and P-selectins

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0432

7 January 2021

Low molecular weight heparin inhibits tumor necrosis factor alpha-induced leukocyte rolling

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0432

7 January 2021

Vascular endothelial growth factor is a chemoattractant for trophoblast cells

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0432

7 January 2021

Low-molecular weight heparin induces in vitro trophoblast invasiveness: role of matrix metalloproteinases and tissue inhibitors

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0432

7 January 2021

Global gene expression analysis identifies molecular pathways distinguishing blastocyst dormancy and activation

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0432

7 January 2021

Interaction of heparin with beta 2-glycoprotein I and antiphospholipid antibodies in vitro

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0432

7 January 2021

Heparin inhibits the binding of beta 2-glycoprotein I to phospholipids and promotes the plasmin-mediated inactivation of this blood protein. Elucidation of the consequences of the two biological events in patients with the anti-phospholipid syndrome

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0432

7 January 2021

Mode of interaction of different polyanions with the first (C1, C1), the second (C2) and the fourth (C4) component of complement--III. Inhibition of C4 and C2 binding site(s) on C1s by polyanions

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0432

7 January 2021

Modulation of the formation of the amplification convertase of complement, C3b, Bb, by native and commercial heparin

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0432

7 January 2021

Structural determinants of the capacity of heparin to inhibit the formation of the human amplification C3 convertase

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0432

7 January 2021

Inhibition of complement-mediated haemolysis in paroxysmal nocturnal haemoglobinuria by heparin or low-molecular weight heparin

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0432

7 January 2021

Heparin prevents antiphospholipid antibody-induced fetal loss by inhibiting complement activation

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0432

7 January 2021

Activation of the alternative complement pathway accompanies disease flares in systemic lupus erythematosus during pregnancy

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0432

7 January 2021

Lupus pregnancy. II. Unusual pattern of hypocomplementemia and thrombocytopenia in the pregnant patient

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0432

7 January 2021

Serum complement values (C3 and C4) to differentiate between systemic lupus activity and pre-eclampsia

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0432

7 January 2021

Identifiers

DOI

10.1038/NCPRHEUM0432

1 reference

Consolidated OpenCitations Corpus – April 2017

OpenCitations bibliographic resource ID

4603141

OpenCitations bibliographic resource ID

4603141

1 reference